Keybank National Association OH raised its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 28.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 74,170 shares of the company’s stock after buying an additional 16,582 shares during the period. Keybank National Association OH’s holdings in Novo Nordisk A/S were worth $2,812,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $287,660,000. State Street Corp boosted its holdings in shares of Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after purchasing an additional 32,641 shares during the period. Royal Bank of Canada grew its stake in Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares during the period. 11.54% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on NVO shares. Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Cfra downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a research report on Tuesday, September 22nd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $59.44.
View Our Latest Stock Analysis on NVO
Novo Nordisk A/S Price Performance
Shares of NVO opened at $41.65 on Monday. The company has a 50 day moving average price of $40.09 and a 200-day moving average price of $43.34. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The stock has a market capitalization of $185.99 billion, a PE ratio of 10.49, a PEG ratio of 1.43 and a beta of 0.70. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.64 and a current ratio of 0.84.
Key Stories Impacting Novo Nordisk A/S
These are some of the NVO stories that stood out recently:
- Positive Sentiment: Novo submitted U.S. and European applications for etavopivat, an investigational once-daily oral treatment for sickle cell disease in patients aged 12 and older. The filings add a potential product opportunity beyond the company’s diabetes and obesity business, but the drug is not yet approved. Novo submits etavopivat to the FDA and EMA
- Neutral Sentiment: Novo enlisted DJ Khaled to share his Wegovy experience as part of a U.S. promotional campaign. The partnership could raise awareness, though its impact on prescriptions and sales is uncertain. Novo and DJ Khaled team up to promote Wegovy
- Negative Sentiment: Eli Lilly secured China’s first approval for an oral GLP-1 weight-loss drug, giving it an early lead in a major market while Novo’s own oral product has yet to launch there. The development highlights intensifying competition in obesity treatment. Eli Lilly beats Novo to oral China GLP-1 market
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
